mRNA Synthesis and Manufacturing Market, 2035
June 27, 2024 04:51 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "mRNA Synthesis and Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Application Area,...
mRNA Therapeutics Market Report 2024-2030: A Projected $31.3 Billion Opportunity Dominated by Moderna, BioNTech, and CureVac
May 29, 2024 06:59 ET
|
Research and Markets
Dublin, May 29, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global mRNA...
Altamira Therapeutics Provides Business Update
May 28, 2024 10:31 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy...
Global RNAi Therapeutics Market Analysis Report 2024-2028: Progress in Collaborations & Associated Deals Bodes Well for the Sector
May 01, 2024 09:16 ET
|
Research and Markets
Dublin, May 01, 2024 (GLOBE NEWSWIRE) -- The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19...
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024 08:00 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new...
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
April 02, 2024 09:05 ET
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals, next-generation RNA therapeutics developer, appoints Dr. Chris Storgard as Chief Medical Officer
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
March 18, 2024 03:00 ET
|
Senisca Ltd
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and...
RNA Therapeutics Market is Expected to Reach $18.0 billion | MarketsandMarkets.
October 02, 2023 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The RNA therapeutics industry is poised for a transformative future as groundbreaking research and technological advancements continue to accelerate the...
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
July 13, 2023 04:00 ET
|
SiSaf Ltd
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis
May 15, 2023 03:00 ET
|
SiSaf Ltd
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...